Gemmer Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Gemmer Asset Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-200	Closed	-$1K	–	1300
2017 Q2	$1K	Hold	200	–	–	﹤0.01%	1231
2017 Q1	$1K	Hold	200	–	–	﹤0.01%	1219
2016 Q4	$1K	Hold	200	–	–	﹤0.01%	1200
2016 Q3	$2K	Hold	200	–	–	﹤0.01%	1186
2016 Q2	$2K	Hold	200	–	–	﹤0.01%	1182
2016 Q1	$1K	Hold	200	–	–	﹤0.01%	1209
2015 Q4	$2K	Hold	200	–	–	﹤0.01%	1182
2015 Q3	$1K	Hold	200	–	–	﹤0.01%	1232
2015 Q2	$2K	Hold	200	–	–	﹤0.01%	1199
2015 Q1	$2K	Hold	200	–	–	﹤0.01%	1237
2014 Q4	$2K	Hold	200	–	–	﹤0.01%	1197
2014 Q3	$1K	Buy	+200	New	+$1.86K	﹤0.01%	1349

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Gemmer Asset Management's ACHN Position: Q3 2017 in Review

Gemmer Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q3 2017, closing a stake of 200 shares — an estimated $1K sold.

Gemmer Asset Management first reported a position in ACHN in Q3 2014 and held it in 12 quarters. The position peaked at $2K in Q3 2016. 125 funds tracked by Wall St. Rank hold ACHN as of Q3 2017.

Gemmer Asset Management reported no remaining Achillion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Gemmer Asset Management sold 200 Achillion Pharmaceuticals shares in Q3 2017, an estimated $1K.
Gemmer Asset Management first reported a position in Achillion Pharmaceuticals in Q3 2014 and held it in 12 quarters.
Gemmer Asset Management's Achillion Pharmaceuticals position peaked at $2K in Q3 2016.
125 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2017.

Based on Gemmer Asset Management's 13F filing for Q3 2017, filed 12 Oct 2017.